Federal Circuit upholds Collegium's Belbuca patents; blocks Alvogen generic until 2032

COLLEGIUM PHARMACEUTICAL, INC

Alvogen conceded infringement; Federal Circuit ruling bars generic entry until 2032 patent expiry (9,901,539 patent).
Court upheld validity of claims in '866 (2027) and '539 (2032) patents; remanded some claims of '866 and '843 patents (2027) for reconsideration.
Decision reinforces strength of Belbuca patent portfolio, protecting key chronic pain product from generic competition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.